Anabolic Steroids

  • Mauro G. Di Pasquale


Recreational and competitive athletes make use of a number of drugs and anabolic supplements to improve their performance and appearance. Anabolic steroids (AS) are the most commonly used and the most infamous of these compounds.


Luteinizing Hormone Serum Testosterone Anabolic Steroid Clinical Endocrinology Serum Testosterone Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abeyawardene, S. A., & Plant, T. M. (1989). Reconciliation of the paradox that testosterone replacement prevents the postcastration hypersecretion of follicle-stimulating hormone in male rhesus monkeys (Macaca mu-latta) with an intact central nervous system but not in hypothalamic-lesioned, gonadotropin-releasing hormone-replaced animals. Biology of Reproduction, 40, 578–584.PubMedCrossRefGoogle Scholar
  2. Albert, D. J., Petrovic, D. M., & Walsh, M. L. (1989). Competitive experience activates testosterone-dependent social aggression toward unfamiliar males. Physiology Behavior; 45, 723–727.PubMedCrossRefGoogle Scholar
  3. Albert, D. J., Jonik, R. H., Watson, N. V., Gorzalka, B. B., & Walsh, M. L. (1990). Hormone-dependent aggression in male rats is proportional to serum testosterone concentration but sexual behavior is not. Physiology Behavior, 48, 409–416.PubMedCrossRefGoogle Scholar
  4. Alen, M., & Hakkinen, K. (1985). Physical health and fitness of an elite bodybuilder during 1 year of self-administering testosterone and anabolic steroids a case study. International Journal of Sports Medicine, 6, 24–29.PubMedCrossRefGoogle Scholar
  5. Alen, M., Reinila, M., & Vihko, R. (1985). Response of serum hormones to androgen administration in power athletes. Medicine Science in Sports Exercise, 17, 354–359.Google Scholar
  6. Alen, M., Rahkila, E, Reinila, M., & Vihko, R. (1987). Androgenic-anabolic steroid effects on serum thyroid, pituitary and steroid hormones in athletes. American Journal of Sports Medicine, 15, 357–361.PubMedCrossRefGoogle Scholar
  7. Annitto, W. J., & Layman, W. A. (1980). Anabolic steroids and acute schizophrenic episode: case reports. Journal of Clinical Psychiatry, 41, 143–144.PubMedGoogle Scholar
  8. Archer, J. (1991). The influence of testosterone on human aggression. British Journal of Psychology, 82, 1–28.CrossRefGoogle Scholar
  9. Ariel, G., & Saville, W. (1972). Anabolic steroids: The physiologic effects of placebos. Medicine Science in Sports Exercise, 4, 124–126.Google Scholar
  10. Bagatell, C. J., Heiman, J. R., Matsumoto, A. M., Rivier, J. E., & Bremner, W. J. (1994). Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. Journal of Clinical Endocrinology Metabolism, 79, 561–567.PubMedCrossRefGoogle Scholar
  11. Bahrke, M. S., Wright, J. E., O’Connor, J. S., Strauss, R. H., Catlin, D. H. (1990). Selected psychological characteristics of anabolic-androgenic steroid users. New England Journal of Medicine, 323, 834–835.PubMedGoogle Scholar
  12. Bahrke, M. S., & Yesalis, C. E. (1994). Weight training. A potential confounding factor in examining the psychological and behavioural effects of anabolic-androgenic steroids [Review]. Sports Medicine, 18, 309–318.PubMedCrossRefGoogle Scholar
  13. Bahrke, M. S., Yesalis, C. E., & Wright, J. E. (1990). Psychological and behavioural effects of endogenous testosterone levels and anabolic-androgenic steroids among males: A review. Sports Medicine, 10, 303–337.PubMedCrossRefGoogle Scholar
  14. Bahrke, M., Wright, J., Strauss, R., & Catlin, D. (1992). Psychological moods and subjectively perceived behavioral and somatic changes accompanying anabolic-androgenic steroid use. American Journal of Sports Medicine, 20, 717–724.PubMedCrossRefGoogle Scholar
  15. Balducci, R., Toscano, V, Casilli, D., Maroder, M., Sciarra, F., & Boscherini, B. (1987). Testicular responsiveness following chronic administration of HCG (1500 IV every six days) in untreated hypogonadotropic hypogonadism. Hormone Metabolic Research, 19, 216–221.CrossRefGoogle Scholar
  16. Balestreri, R., Bertolini, S., Chiodini, G., & Ronzitti, M. (1971). Pituitary inhibitory and non-inhibitory effects of various anabolic 17-alkylating steroids. Archivo e Maragliano di Patologia e Clinica, 27, 123–135.Google Scholar
  17. Baranowska, B., Jeske, W, Niewiadomska, A., Rozbicka, G., Walczak, L., & Zgliczynski, S. (1983). Enhanced serum prolactin concentration after metoclopramide stimulation in idiopathic oligozoospermia and azoospermia. Andrologia, 15 (Special No.), 554–559.PubMedCrossRefGoogle Scholar
  18. Barker, S. (1987). Oxymethalone and aggression. British Journal of Psychiatry, 151, 564.PubMedGoogle Scholar
  19. Bhasin, S., Storer, T. W, Berman, N., Callegari, C., Clevenger, B., Phillips, J., Blunnell, T., Tricker, R., Shirazi, A., & Casaburi, R. (1996). The effect of supraphysiologic doses of testosterone on muscle size and strength in normal men. New England Journal of Medicine, 335, 1–7.PubMedCrossRefGoogle Scholar
  20. Bjorkqvist, K., Nygren, T., Bjorklund, A. C., & Bjorkgvist, S. E. (1994). Testosterone intake and aggressiveness: Real effect or anticipation? Aggressive Behavior; 20, 18–26.Google Scholar
  21. Blank, D. M., Clark, R. V, Heymsfield, S. B., Rudman, D., & Blank, M. (1994). Endogenous opioids and hypogonadism in human obesity. Brain Research Bulletin, 34, 571–574.PubMedCrossRefGoogle Scholar
  22. Bradley, A. J. (1987). Stress and mortality in the red-tailed phascogale, Phascogale calura (Marsupialia: Dasyuridae). General Comparative Endocrinology, 67, 85–100.CrossRefGoogle Scholar
  23. Brower K. (1989). Rehabilitation for anabolic-androgenic steroid dependence. Clinics in Sports Medicine, 1, 171–181.Google Scholar
  24. Brower, K. J. (1993a). Anabolic steroids: Potential for physical and psychological dependence. In C. Yesalis (Ed.), Anabolic steroids in sport and exercise (pp. 193–213 ). Champaign, IL: Human Kinetics.Google Scholar
  25. Brower, K. J. (1993b). Assessment and treatment of anabolic steroid withdrawal. In C. Yesalis (Ed), Anabolic steroids in sport and exercise (pp. 231–250 ). Champaign, IL: Human Kinetics.Google Scholar
  26. Brower, K. J., Blow, F. C., Beresford, T. P, & Fuelling, C. (1989). Anabolic-androgenic steroid dependence. Journal of Clinical Psychiatry, 50, 31–33.PubMedGoogle Scholar
  27. Brower, K. J., Blow, E C., Eliopulos, G. A., & Beresford, T. P. (1989). Letters to the Editor: Anabolic androgenic steroids and suicide. American Journal of Psychiatry, 146, 1075.PubMedGoogle Scholar
  28. Brower, K. J., Eliopulos, G. A., Blow, F. C., Catlin, D. H., & Beresford, T. P. (1990). Evidence for physical and psychological dependence on anabolic androgenic steroids in eight weight lifters. American Journal of Psychiatry, 147, 510–512.PubMedGoogle Scholar
  29. Brower, K., Blow, F, Young, J., & Hill, E. (1991). Symptoms and correlates of anabolic-androgenic steroid dependence. British Journal of Addiction, 86, 759–768.PubMedCrossRefGoogle Scholar
  30. Celotti, F., Avogadri, N., Melcangi, R. C, Milani, S., & Negri Cesi, P. (1984). Cyclophenil, a non-steroidal compound with a higher central than peripheral oestrogenic activity: Study of its effects on uterine growth and on some central parameters in castrated female rats. Acta Endocrinologica, 107, 340–345.PubMedGoogle Scholar
  31. Choi, P. Y. L., Parrott, A. C., & Cowan, D. (1990). High-dose anabolic steroids in strength athletes: Effects upon hostility and aggression. Human Psychopharmacology, 5, 349–356.CrossRefGoogle Scholar
  32. Christiansen, K., Knussmann, R. (1987). Androgen levels and components of aggressive behavior in men. Hormones Behavior, 21, 170–180.CrossRefGoogle Scholar
  33. Clerico, A., Ferdeghini, M., Palombo, C., Leoncini, R., Del Chicca, M., Sardano, G., & Mariani, G. (1981). Effect of anabolic treatment on the serum levels of gonadotropins, testosterone, prolactin, thyroid hormones and myoglobin of male athletes under physical training. Journal of Nuclear Medicine Allied Sciences, 25, 79–88.Google Scholar
  34. Conacher, G., & Workman, D. (1989). Violent crime possibly associated with anabolic steroid use. American Journal of Psychiatry, 146, 679.PubMedGoogle Scholar
  35. Dalby, J. (1992). Brief anabolic steroid use and sustained behavioral reaction. American Journal of Psychiatry, 149, 271–272.PubMedGoogle Scholar
  36. Dalkin, A. C., Haisenleder, D. J., Ortolano, G. A., Ellis, T. R., & Marshall, J. C. (1989). The frequency of gonadotropin-releasing-hormone stimulation differentially regulates gonadotropin subunit messenger ribonucleic acid expression. Endocrinology, 125, 917–924.PubMedCrossRefGoogle Scholar
  37. De Lignieres, B., & Mauvais-Jarvis, P. (1979). Hormones in depressive illness. The role of cortisol and sexual steroids. Annales de Biologie Clinique, 37, 49–57.PubMedGoogle Scholar
  38. del Pozo, E., & Martin-Perez, J. (1985). Effect of dopamine receptor stimulation on the inhibition of LH pulsatility by a met-enkephaline (FK 33–824). Acta Neurochirurgica, 75, 88–90.PubMedCrossRefGoogle Scholar
  39. Delville, Y., Mansour, K. M., & Ferris, C. E (1996). Testosterone facilitates aggression by modulating vasopressin receptors in the hypothalamus. Physiology Behavior, 60, 25–29.PubMedCrossRefGoogle Scholar
  40. Di Pasquale, M. G. (1991). Polypharmacy-Anabolic steroids and beyond. Drugs in Sports, Premier Issue, 1–2.Google Scholar
  41. Dunkel, L., & Huhtaniemi, I. (1985). Abnormal prolactin secretion in prepubertal boys with hypogonadotrophic hypogonadism-Possible involvement in regulation of testicular steroidogenesis. International Journal of Andrology, 8, 385–392.PubMedCrossRefGoogle Scholar
  42. Egginton, S. (1987). Effects of an anabolic hormone on striated muscle growth and performance. P. Jlugers Archiv-European Journal of Physiology, 410, 349–355.CrossRefGoogle Scholar
  43. Falaschi, E, Frajese, G., Sciarra, E, Rocco, A., & Conti, C. (1978). Influence of hyperprolactinaemia due to metoclopramide on gonadal function in men. Clinical Endocrinology, 8, 427–433.PubMedCrossRefGoogle Scholar
  44. Finkelstein, J. S., Spratt, D. I., O’Dea, L. S., Whitcomb, R., Klibanski, A., Schoenfeld, D., & Crowley, W. (1989). Pulsatile gonadotropin secretion after discontinuation of long-term gonadotropin-releasing hormone (GnRH) administration in a subset of GnRH-deficient men. Journal of Clinical Endocrinology Metabolism, 69, 377–385.PubMedCrossRefGoogle Scholar
  45. Foresta, C., Scanelli, G., Tramarin, A., & Scandellari, C. (1985). Serotonin but not dopamine is involved in the naloxone-induced luteinizing hormone release in man. Fertility Sterility, 43, 447–450.Google Scholar
  46. Frajese, G., Lazzari, R., Magnani, A., Moretti, C., Sforza, V, & Nerozzi, D. (1990), Neurotransmitter, opiodergic system, steroid-hormone interaction and involvement in the replacement therapy of sexual disorders. Journal of Steroid Biochemistry Molecular Biology, 37, 411–419.CrossRefGoogle Scholar
  47. Frankle, M. A., Eichberg, R., & Zachariah, S. B. (1988). Anabolic androgenic steroids and a stroke in an athlete: Case report. Archives of Physical Medicine Rehabilitation, 69, 632–633.Google Scholar
  48. Freinhar, J. P., & Alvarez, W. (1985). Androgen-induced Hypomania [letter]. Journal of Clinical Psychiatry, 46, 354–355.PubMedGoogle Scholar
  49. Galligani, N., Renck, A., & Hansen, S. (1996). Personality profile of men using anabolic androgenic steroids. Hormones Behavior, 30, 170–175.CrossRefGoogle Scholar
  50. Giannini, J. A., Miller, N., & Kocjan, D. (1991). Treating steroid abuse: A psychiatric perspective. Clinical Pediatrics, 30, 538–542.PubMedCrossRefGoogle Scholar
  51. Gitlin, M. J. (1994). Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches. Journal of Clinical Psychiatry, 55, 406–413.PubMedGoogle Scholar
  52. Glass, A. R. (1988). Pituitary-testicular reserve in men with low serum testosterone and normal serum luteinizing hormone. Journal of Andrology, 9, 224–230.PubMedGoogle Scholar
  53. Goodman Gilman, A., Goodman, L. S., Rall, T. N., & Murad, F. (Eds.). (1985). The pharmacological basis of therapeutics, 7th edition. New York: Macmillan.Google Scholar
  54. Griggs, R. C., Kingston, W, Jozefowicz, R. E, Herr, B. E., Forbes, G., & Halliday, D. (1989). Effect of testosterone on muscle mass and muscle protein synthesis. Journal of Applied Physiology (United States), 66, 498–503.Google Scholar
  55. Hannan, C. J., Fried, K. E., Zold, A., Kettler, T. M., & Plymate, S. R. (1991). Psychological and serum homovanillic acid changes in men administered androgenic steroids. Psychoneuroendocrinology, 16, 335–343.PubMedCrossRefGoogle Scholar
  56. Haupt, H. A., & Rovere, G. D. (1984). Anabolic steroids: A review of the literature. American Journal of Sports Medicine, 12, 469–484.PubMedCrossRefGoogle Scholar
  57. Hobbs, C. J., Plymate, S. R., Bell, B. K., & Patience, T. H. (1991). The effect of androgens on glucose tolerance. Clinical Research, 39, 384A.Google Scholar
  58. Holma, P., & Adlercreutz, H. (1976). Effect of an anabolic steroid (metandienon) on plasma LH-FSH, and testosterone and on the response to intravenous administration of LRH. Acta Endocrinologica, 83, 856–864.PubMedGoogle Scholar
  59. Jezova, D., Komadel, L., & Mikulaj, L. (1987). Plasma testosterone response to repeated human chorionic gonadotropin administration is increased in trained athletes. Endocrinologica Experimentalis, 21, 143–147.Google Scholar
  60. Kashkin, K. B., & Kleber, H. D. (1989). Hooked on hormones? An anabolic steroid addiction hypothesis. Journal of the American Medical Association, 262, 3166–3170.PubMedCrossRefGoogle Scholar
  61. Kehoe, P. (1982). The relevance of anabolic steroids to middle distance running. Australian Track and Field Coaches Association (monograph).Google Scholar
  62. Kenyon, A. T. (1938). The effect of testosterone propionate on the genitalia, prostrate, secondary sex characters, and body weight in eunuchoidism. Endocrinology, 23, 121–134.CrossRefGoogle Scholar
  63. Kenyon, A. T. ( 1942, September). The first Josiah Macy Jr. Conference on bone and wound healing.Google Scholar
  64. Kenyon, A. T., Knowlton, K., Lotwin, G., & Sandford, I. (1942). Metabolic response of aged men to testosterone propionate. Journal of Clinical Endocrinology, 2, 690–695.CrossRefGoogle Scholar
  65. Kenyon, A. T., Knowlton, K., & Sandford, I. (1944). The anabolic effects of the androgens and somatic growth in man. Annals of Internal Medicine, 20, 632–654.Google Scholar
  66. Kilshawm, B. H., Harkness, R. A., Hobson, B. M., & Smith, A. W. (1975). The effects of large doses of the anabolic steroid, methandrostenolone, on an athlete. Clinical Endocrinology, 4, 537–541.CrossRefGoogle Scholar
  67. Kiraly, C. L., Collan, Y., & Alen, M. (1987). Effect of testosterone and anabolic steroids on the size of sebaceous glands in power athletes. American Journal of Dermatopathology, 9, 515–519.Google Scholar
  68. Kletter, G. B., Foster, C. M., Beitins, 1. Z., Marshall, J., & Kelch, R. (1992). Acute effects of testosterone infusion and naloxone on luteinizing hormone secretion in normal men. Journal of Clinical Endocrinology Metabolism, 75, 1215–1219.Google Scholar
  69. Kletter, G. B., Foster, C. M., Brown, M. B., Beitins, 1., Marshall, J., & Kelch, R. (1994). Nocturnal naloxone fails to reverse the suppressive effects of testosterone infusion on luteinizing hormone secretion in pubertal boys. Journal of Clinical Endocrinology Metabolism, 79, 1147–1151.Google Scholar
  70. Kouri, E. M., Lukas, S. E., Pope, H. G., Jr., & Oliva, P. S. (1995). Increased aggressive responding in male volunteers following the administration of gradually increasing doses of testosterone cypionate. Drug and Alcohol Dependence, 40, 73–79.PubMedCrossRefGoogle Scholar
  71. Kruskemper, H. L. (1968). Anabolic steroids (C. H. Doering, Trans.). New York: Academic Press.Google Scholar
  72. Kulin, H. E., & Reiter, E. O. (1972). Gonadotropin suppression by low dose estrogen in men-Evidence for differential effects upon FSH and LH. Journal of Clinical Endocrinology Metabolism, 35, 836–839.PubMedCrossRefGoogle Scholar
  73. Labbate, L. A., & Pollack, M. H. (1994). Treatment of fluoxetine-induced sexual dysfunction with bupropion: a case report. Annals of Clinical Psychiatry, 6, 13–15.PubMedCrossRefGoogle Scholar
  74. Lefavi, R. G., Reeve, T. G., & Newland, M. C. (1990). Relationship between anabolic steroid use and selected psychological parameters in male bodybuilders. Journal of Sport Behavior, 13, 157–166.Google Scholar
  75. Le Greves, P, Huang, W., Johansson, P, Thornwall, M., Zhou, Q., & Nyberg, E (1997). Effects of an anabolic-androgenic steroid on the regulation of the NMDA receptor NRI, NR2A and NR2B subunit mRNAs in brain regions of the male rat. Neuroscience Letters, 18, 61–64.CrossRefGoogle Scholar
  76. Lesch, K. P, Muller, U., Rupprecht, R., Kruse, K., & Schulte, H. (1989). Endocrine responses to growth hormone-releasing hormone, thyrotropin-releasing hormone and corticotropin-releasing hormone in depression. Acta Psychiatrica Scandinavica, 79, 597–602.PubMedCrossRefGoogle Scholar
  77. Libstag, K. (1990). The effects of anabolic steroids on measured personality traits of male weight trainers. Dissertation Abstracts International, 51, 40–91.Google Scholar
  78. Lindstrom, M., Nilsson, A., Katzman, P., Janzon, L., & Dymling, J. (1990). Use of anabolic-androgenic steroids among bodybuilders: Frequency and attitudes. Journal of Internal Medicine, 227, 407–41 I.PubMedCrossRefGoogle Scholar
  79. Maddocks, S., & Setchell, B. P (1989). Effect of a single injection of human chorionic gonadotrophin on testosterone levels in testicular interstitial fluid, and in testicular and peripheral venous blood in adult rats. Journal of Endocrinology, 121, 311–316.PubMedCrossRefGoogle Scholar
  80. Maggi, M., De Feo, M. L., Mannelli, M., Delitala, G., & Forti, G. (1985). Naloxone administration does not affect gonadotrophin secretion in male patients with isolated hypogonadotrophic hypogonadism. Acta Endocrinologica, 109, 153–157.PubMedGoogle Scholar
  81. Malone, D., & Dimeff, R. (1992). The use of fluoxetine in depression associated with anabolic steroid withdrawal: A case series. Journal of Clinical Psychiatry, 53, 130–132.PubMedGoogle Scholar
  82. Martikainen, H., Alen, M., Rahkila, P, & Vihko, R. (1986). Testicular responsiveness to human chorionic gonadotrophin during transient hypogonadotrophic hypogonadism induced by androgenic/anabolic steroids in power athletes. Journal of Steroid Biochemistry, 25, 109–112.PubMedCrossRefGoogle Scholar
  83. Masonis, A. E., & McCarthy, M. P. (1996). Direct interactions of androgenic/anabolic steroids with the peripheral benzodiazepine receptor in rat brain: Implications for the psychological and physiological manifestations of androgenic/anabolic steroid abuse. Journal of Steroid Biochemistry and Molecular Biology, 58, 551–555.PubMedCrossRefGoogle Scholar
  84. McNutt, R. A., Ferenchick, G. S., Kirlin, E C., & Hamlin, N. J. (1988). Acute myocardial infarction in a 22year-old world class weight lifter using anabolic steroids. American Journal of Cardiology, 62, 164.PubMedCrossRefGoogle Scholar
  85. Mikuma, N., Kumamoto, Y., Maruta, H., & Nitta, T. (1994). Role of the hypothalamic opioidergic system in the control of gonadotropin secretion in elderly men. Andrologia, 26, 39–45.PubMedCrossRefGoogle Scholar
  86. Nakagawa, K., Obara, T., Matsubara, M., & Kubo, M. (1982). Relationship of changes in serum concentrations of prolactin and testosterone during dopaminergic modulation in males. Clinical Endocrinology, 17, 345–352.PubMedCrossRefGoogle Scholar
  87. Nilsson, P. M., Moller, L., & Solstad, K. (1995). Adverse effects of psychosocial stress on gonadal function and insulin levels in middle-aged males. Journal of Internal Medicine, 137, 479–486.CrossRefGoogle Scholar
  88. Perry, P. J., Andersen, K. H., & Yates, W. R. (1990). Illicit anabolic steroid use in athletes: A case series analysis. American Journal of Sports Medicine, 18, 422–428.PubMedCrossRefGoogle Scholar
  89. Perry, P. J., Yates, W. R., & Andersen, K. H. (1990). Psychiatric symptoms associated with anabolic steroids: A controlled, retrospective study. Annals of Clinical Psychiatry, 2, 11–17.CrossRefGoogle Scholar
  90. Pope, H. G., & Katz, D. L. (1987). Bodybuilder’s psychosis. Lancet, 1, 863.PubMedCrossRefGoogle Scholar
  91. Pope, H. G., & Katz, D. L. (1988). Affective and psychotic symptoms associated with anabolic steroid use. American Journal of Psychiatry, 145, 487–490.PubMedGoogle Scholar
  92. Pope, H. G., & Katz, D. L. (1990). Homicide and near-homicide by anabolic steroid users. Journal of Clinical Psychiatry, 51, 28–31.PubMedGoogle Scholar
  93. Pope, H. G., Jr., Gruber, A. J., Choi, P., Olivardia, R., & Phillips, K. A. (1997). An underrecognized form of body dysmorphic disorder. Psychosomatics, 38, 548–557.PubMedCrossRefGoogle Scholar
  94. Porcerelli, J. H., & Sandler, B. A. (1995). Narcissism and empathy in steroid users. American Journal of Psychiatry, 152, 1672–1674.PubMedGoogle Scholar
  95. Prat, J., Gray, G. F., Stolley, P. D., & Coleman, J. W. (1977). Wilms’ tumor in an adult associated with androgen abuse. Journal of the American Medical Association, 237, 2322–2323.PubMedCrossRefGoogle Scholar
  96. Rasmussen, D. D., Kennedy, B. P., Ziegler, M. G., & Nett, T. M. (1988). Endogenous opioid inhibition and facilitation of gonadotropin-releasing hormone release from the median eminence in vitro: potential role of catecholamines. Endocrinology, 123, 2916–2921.PubMedCrossRefGoogle Scholar
  97. Repcekova, D., & Mikulaj, L. (1977). Plasma testosterone response to HCG in normal men without and after administration of anabolic drug. Endokrinologie, 69, 115–118.PubMedGoogle Scholar
  98. Roberts, J. T., & Essenhigh, D. M. (1986). Adenocarcinoma of prostate in 40-year-old body-builder [Letter]. Lancet, 2, 742.PubMedCrossRefGoogle Scholar
  99. Rockhold, R. W. (1993). Cardiovascular toxicity of anabolic steroids. Annual Review of Pharmacology Toxicology, 33, 497–520.CrossRefGoogle Scholar
  100. Rowlands, R. P., & Nicholson, G. W. (1929). Growth of left testicle with precocious sexual and bodily development (macro-genitosomia) Guy’s Hospital Report, 79, 401–408.Google Scholar
  101. Ruokonen, A., Alen, M., Bolton, N., & Vihko, R. (1985). Response of serum testosterone and its precursor steroids, SHBG and CBG to anabolic steroid and testosterone self-administration in man. Journal of Steroid Biochemistry, 23, 33–38.PubMedCrossRefGoogle Scholar
  102. Ryzhenkov, V. E., Bekhtereva, E. P., & Sapronov, N. S. (1974). Role of the limbic structures in the mechanism of action of glucocorticoids and estrogens on hypothalamic control of pituitary adrenocorticotropic and gonadotropic functions. Bulletin of Experimental Biology Medicine, 77, 362–265.Google Scholar
  103. Sacchi, E. (1895). A case of infantile gigantism (pedomacrosomia) with a tumor of the testicle. Riv. sper Freniat., 21, 149–161.Google Scholar
  104. Schatzberg, A. F., Rothschild, A. J., Langlais, P. J., Bird, E. D., & Cole, J. O. (1985). A corticosteroid/dopamine hypothesis for psychotic depression and related states. Journal of Psychiatric Research, 19, 57–64.PubMedCrossRefGoogle Scholar
  105. Schlinger, B. A., & Callard, G. V. (1989). Aromatase activity in quail brain: correlation with aggressiveness. Endocrinology, 124, 437–43.PubMedCrossRefGoogle Scholar
  106. Schulte, H. M., Hall, M. J., & Boyer, M. (1993). Domestic violence associated with anabolic steroid abuse [Letter to the editor]. American Journal of Psychiatry, 150, 348.PubMedGoogle Scholar
  107. Schulte-Beerbuhl, M., & Nieschlag, E. (1980). Comparison of testosterone, dihydrotestosterone, luteinizing hormone, and follicle-stimulating hormone in serum after injection of testosterone enanthate or testosterone cypionate. Fertility Sterility, 33, 201–203.Google Scholar
  108. Sheckter, C. B., Matsumoto, A. M., & Bremner, W. J. (1989). Testosterone administration inhibits gonadotropin secretion by an effect directly on the human pituitary. Journal of Clinical Endocrinology Metabolism, 68, 397–401.PubMedCrossRefGoogle Scholar
  109. Siegel, J. M. (1986). The Multidimensional Anger Inventory. Journal of Personality Social Psychology, 51, 191–200.CrossRefGoogle Scholar
  110. Smals, A. G., Pieters, G. E, Smals, A. E., Hermus, A. R., Boers, G. H., Raemaekers, J. M., Benraad, T. J., & Kloppenborg, P. W. (1987). Reciprocal inhibition of the long-acting luteinizing hormone releasing hormone agonist Buserelin and human chorionic gonadotropin in stimulating Leydig cell steroidogenesis. Journal of Steroid Biochemistry, 28, 743–747.PubMedCrossRefGoogle Scholar
  111. Soe, K. L., Soe, M., & Gluud, C. N. (1994). [Liver pathology associated with anabolic androgenic steroids]. Ugeskrift for Laeger, 156, 2585–2588.Google Scholar
  112. Spitz, I. M., LeRoith, D., Livshin, Y., Zylber-Haran, E., Trestian, S., Laufer, N., Ron, M., Palti, Z., & Schenker, J. (1980). Exaggerated prolactin response to thyrotropin-releasing hormone and metoclopramide in primary testicular failure. Fertility Sterility, 34, 573–580.Google Scholar
  113. Stannard, J. P., & Bucknell, A. L. (1993). Rupture of the triceps tendon associated with steroid injections. American Journal of Sports Medicine, 21, 482–485.PubMedCrossRefGoogle Scholar
  114. Strauss, R., Liggett, M., & Lanese, R. (1985). Anabolic steroid use and perceived effects in ten weight-trained women athletes. Journal of the American Medical Association, 253, 2871–2873.PubMedCrossRefGoogle Scholar
  115. Strauss, R. H., Wright, J. E., Finerman, G. A. M., & Catlin, D. H. (1983). Side effects of anabolic steroids in weight-trained men. Physician and Sports Medicine, 11, 86–88,91–93, 95, 98.Google Scholar
  116. Su, T. P, Pagliaro, M., Schmidt, P. J., Pickar, D., Wolkowitz, O., & Rubinow, D. R. (1993). Neuropsychiatric effects of anabolic steroids in male normal volunteers. Journal of the American Medical Association, 269, 2760–2764.PubMedCrossRefGoogle Scholar
  117. Taylor, W. (1987). Anabolic steroids: A plea for control. Chiropractic Sports Medicine, 1, 47–52.Google Scholar
  118. Taylor, W. N. (1985). Hormonal manipulation. A new era of monstrous athletes. Jefferson, NC: McFarland.Google Scholar
  119. Tennant, E, Black, D. L., & Voy, R. O. (1988). Correspondence: Anabolic steroid dependence with opioid-type features. New England Journal of Medicine, 319, 578.PubMedCrossRefGoogle Scholar
  120. Tepavcevic, D., Giljevic, Z., Korsic, M., Halimi, S., Suchanek, E., Jelic, T., Aganovic, I., Kozic, B., & Playsic, V. (1994). Effects of ritanserin, a novel serotonin-S2 receptor antagonist, on the secretion of pituitary hormones in normal humans. Journal of Endocrinological Investigation, 17, 1–5.PubMedGoogle Scholar
  121. Tilzey, A., Heptonstall, J., & Hamblin, T. (1981). Toxic confusional state and choreiform movements after treatment with anabolic steroids. British Medical Journal, 285, 349–350.CrossRefGoogle Scholar
  122. Tinajero, J. C., Fabbri, A., & Dufau, M. L. (1992). Regulation of corticotropin-releasing factor secretion from Leydig cells by serotonin. Endocrinology, 130, 1780–1788.PubMedCrossRefGoogle Scholar
  123. Van Vugt, D. A., & Meites, J. (1980). Influence of endogenous opiates on anterior pituitary function [Review]. Federation Proceedings, 39, 2533–2538.PubMedGoogle Scholar
  124. Vanderstichele, H., Eechaute, W, Lacroix, E., & Leusen, I. (1989). Effect of tamoxifen on the activity of enzymes of testicular steroidogenesis. Steroids, 53, 713–726.PubMedCrossRefGoogle Scholar
  125. Vermeulen, A. (1994). [Neuroendocrinological aspects of aging]. Verhandelingen-Koninklijke Academie voor Geneeskunde van Belgie, 56,267–280.Google Scholar
  126. Vermeulen, A., Kaufman, J. M. (1995). Ageing of the hypothalamo-pituitary-testicular axis in men. Hormone Research, 43, 25–28.PubMedCrossRefGoogle Scholar
  127. Vida, J. A. (1969). Androgens and anabolic agents. New York: Academic Press.Google Scholar
  128. Wanderley, M. I., Favaretto, A. L., Valenca, M. M., Hattori, M., Wakabayaski, K., & Antunes-Rodrigues, J. (1989). Modulatory effects of adrenergic agonists on testosterone secretion from rat dispersed testicular cells or Percoll-purified Leydig cells. Brazilian Journal of Medical Biological Research, 22, 1421–1429.Google Scholar
  129. Webb, O. L., Laskarzewski, P. M., & Glueck, C. J. (1985). Severe depression of high-density lipoprotein cholesterol levels in weight lifters and body builders by self-administered exogenous testosterone and anabolic-androgenic steroids. Metabolism, 33, 971–975. Abstract/Commentary: 1986 Year Book of Endocrinology, Article 8–8.Google Scholar
  130. Welder, A. A., & Melchert, R. B. (1993). Cardiotoxic effects of cocaine and anabolic-androgenic steroids in the athlete [Review]. Journal of Pharmacological Toxicological Methods, 29, 61–68.CrossRefGoogle Scholar
  131. Williams, T. D., Lightman, S. L., Johnson, M. R., Carmichael, D., & Bannister, R. (1989). Selective defect in gonadotrophin secretion in patients with autonomic failure. Clinical Endocrinology, 30, 285–292.PubMedCrossRefGoogle Scholar
  132. Williamson, D. J., & Young, A. H. (1992). Psychiatric effects of androgenic and anabolic-androgenic steroid abuse in men: A brief review of the literature. Journal of Psychopharmacology, 6, 20–26.PubMedCrossRefGoogle Scholar
  133. Wilson, 1. C., Prange, A. J., & Lara, P. P. (1974). Methyl-testosterone and imipramine in men: Conversion of depression to paranoid reaction. American Journal of Psychiatry, 131, 21–24.Google Scholar
  134. Wilson, J. (1988). Androgen abuse by athletes. Endocrinology Review, 9, 181–199.CrossRefGoogle Scholar
  135. Windsor, R., & Dumitru, D. (1989). Prevalence of anabolic steroid use by male and female adolescents. Medicine Science in Sports Exercise (United States), 21, 494–497.Google Scholar
  136. Wolkowitz, O. M. (1994). Prospective controlled studies of the behavioral and biological effects of exogenous corticosteroids [Review]. Psychoneuroendocrinology, 19, 233–255.PubMedCrossRefGoogle Scholar
  137. Woodard, T. L., Burghen, G. A., Kitabchi, A. E., & Wilmas, J. A. (1981). Glucose intolerance and insulin resistance in aplastic anemia treated with oxymethalone. Journal of Clinical Endocrinology Metabolism, 53, 905–908.PubMedCrossRefGoogle Scholar
  138. World Health Organization Task Force. (1990). Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet, 336, 955–959.Google Scholar
  139. Wroblewska, A. M. (1997). Androgenic-anabolic steroids and body dysmorphia in young men. Journal of Psychometric Research, 42, 225–234.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Mauro G. Di Pasquale
    • 1
  1. 1.Department of Physical and Health EducationUniversity of TorontoTorontoCanada

Personalised recommendations